Infections relevant to lung transplantation

Proceedings of the American Thoracic Society

Volumn 6, Issue 1, 2009, Pages 94-100

  Remund, Kaspar F ^a   Best, Matthew ^a   Egan, Jim J ^a  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Infection; Lung transplantation; Prophylaxis

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; FLUCONAZOLE; GANCICLOVIR; IMMUNOGLOBULIN; INFLUENZA VACCINE; ITRACONAZOLE; MACROLIDE; PIPERACILLIN PLUS TAZOBACTAM; PNEUMOCOCCUS VACCINE; SULFAMETHOXAZOLE; TRIMETHOPRIM; VALGANCICLOVIR; VORICONAZOLE;

ANTIMICROBIAL THERAPY; ASPERGILLOSIS; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BACTERIAL VIRULENCE; CANDIDA; CANDIDEMIA; CHLAMYDIAL PNEUMONIA; CHLAMYDOPHILA PNEUMONIAE; CORONAVIRUS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FLAVIVIRUS; FUSARIUM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA VACCINATION; LUNG TRANSPLANTATION; MYCOSIS; PICORNAVIRUS; PSEUDOMONAS AERUGINOSA; RESPIRATORY VIRUS; REVIEW; SCEDOSPORIUM; VIRUS DETECTION; VIRUS INFECTION; ZYGOMYCETES;

ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, MICROBIAL; GRAFT REJECTION; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; LUNG TRANSPLANTATION; OPPORTUNISTIC INFECTIONS; PREMEDICATION; RESPIRATORY TRACT INFECTIONS; RISK FACTORS; SURGICAL WOUND INFECTION; VACCINATION;

EID: 58549086959     PISSN: 15463222     EISSN: None     Source Type: Journal    
DOI: 10.1513/pats.200809-113GO     Document Type: Review

References (82)

1. Speich R, van der Bij W. Epidemiology and management after lung transplantation. Clin Infect Dis 2001;33:S58-S65.
2. Kotloff RM, Vivek NA, Crawford SW. Pulmonary complications of solid organ and hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2004;170:22-48.
3. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007;357:2601-2614.
4. Aquilar-Guisado M, Givalda J, Ussetti P, Ramos A, Morales P, Blanes M, Bou G, de la Torre-Cisneros J, Roman A, Borro JM, et al. Pneumonia after lung transplantation in the Resitra cohort: a multicenter prospective study. Am J Transplant 2007;7:1989-1996.
5. Valentine VG, Bonvillain BS, Gupta MR, Lombard GA, La Place SG, Dhillon GS, Wang G. Infections in lung allograft recipients: ganciclovir era. J Heart Lung Transplant 2008;27:528-535.
6. Dauber JH, Paradis IL, Dummer JS. Infectious complications in pulmonary allograft recipients. Clin Chest Med 1990;11:291-308.
7. Weill D, Dey GC, Hicks RA, Young KR, Zorn GL, Kirklin JK, Early L, McGiffin DC. A positive donor gram stain does not predict outcome following lung transplantation. J Heart Lung Transplant 2002;21:555-558.
8. Sharples LD, McNeil K, Stewart S, Wallwork J. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J Heart Lung Transplant 2002;21:271-281.
9. Flume PA, Egan TM, Paradowski LJ, Detterbeck FC, Thompson JT, Yankaskas JR Jr. Infectious complications of lung transplantation: impact of cystic fibrosis. Am J Respir Crit Care Med 1994;149:1601-1607.
10. Kanj SS, Tapson V, Davis D, Madden J, Browning I. Infections in patients with cystic fibrosis following lung transplantation. Chest 1997;112:924-930.
11. Nunley DR, Grgurich W, Iacono AT, Yousem S, Ohori NP, Keenan RJ, Dauber JH. Allograft colonization and infections with pseudomonas in cystic fibrosis lung transplant recipients. Chest 1998;113:1235-1243.
12. Bonnvillain RW, Valentine VG, Lombard GA, La Place SG, Dhillon G, Wang G. Post-operative infections in cystic fibrosis and non cystic fibrosis patients after lung transplantation. J Heart Lung Transplant 2007;26:890-897.
13. Botha P, Archer L, Anderson RL, Lordan J, Dark JH, Corris PA, Gould K, Fisher AJ. Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation 2008;85:771-774.
14. Walter S, Gudowius P, Bosshammer J, Roemling U, Weissbrodt H, Schuermann W, van der Hardt H, Tuemmler B. Epidemiology of chronic Pseudomonas aeruginosa infections in the airways of lung transplant recipients with cystic fibrosis. Thorax 1997;52:318-321.
15. Vos R, Vanaudenaerde BM, Geudens N, Dupont LJ, Van Raemdonck DE, Verleden GM. Pseudomonal airway colonisation: risk factor for bronchiolitis obliterans syndrome after lung transplantation? Eur Respir J 2008;31:1037-1045.
16. Boussaud V, Guillemain R, Grenet D, Coley N, Souilamas R, Bonnette P, Stern M. Clinical outcome following lung transplantation in cystic fibrosis patients colonized with Burkholderia cepacia complex: results from two French centers. Thorax 2008;63:732-737.
17. Aris RM, Routh JC, LiPuma JJ, Heath DG, Gilligan PH. Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex: survival linked to genomovar type. Am J Respir Crit Care Med 2001;164:2102-2106.
18. Egan JJ, McNeil K, Bookless B, Gould K, Corris P, Higenbottam T, Webb AK, Woodcock AA. Post-transplantation survival of cystic fibrosis patients infected with Pseudomonas cepacia. Lancet 1994;344:552-553.
19. Glanville AR, Gencay M, Tamm M, Chhajed P, Plit M, Hopkins P, Aboyoun C, Roth M, Malouf M. Chlamydia pneumoniae infection after lung transplantation. J Heart Lung Transplant 2005;24:131-136.
20. Miller RA, Lanza LA, Kline JN, Geist LJ. Mycobacterium tuberculosis in lung transplant recipients. Am J Respir Crit Care Med 1995;152:374-376.
21. Ridgeway AI, Warner GS, Phillips P, Forshag MS, McGriffin DC, Harden JW, Harris RH, Benjamin WH, Zorn GL, Dunlap NE. Transmission of Mycobacterium tuberculosis to recipients of single lung transplants from the same donor. Am J Respir Crit Care Med 1996;153:1166-1168.
22. Malouf MA, Glanville AR. The spectrum of mycobacterial infection after lung transplantation. Am J Respir Crit Care Med 1999;160:1611-1616.
23. Kesten S, Chaparro C. Mycobacterial infections in lung transplant recipients. Chest 1999;115:741-745.
24. Chalermskulrat W, Sood N, Neuringer IP, Hecker TM, Chang L, Rivera MP, Paradowski LJ, Aris RM. Non-tuberculous mycobacteria in end stage cysticfibrosis: implications for lung transplantation. Thorax 2006;61:507-513.
25. Husain S, Chan KM, Palmer SM, Hadjiliadis D, Humar A, McCurry KR, Wagener MM, Singh N. Bacteraemia in lung transplant recipients in the current era. Am J Transplant 2006;6:3000-3007.
26. Zamora MR. Cytomegalivirus in lung transplantation. Am J Transplant 2004;4:1219-1226.
27. Balthesen M, Messerle M, Reddehase MJ. Lungs are a major organ site of cytomegalovirus latency and recurrence. J Virol 1993;67:5360-5366.
28. Zamora MR, Davis D, Leonard C; CMV Advisory Board Expert Committee. Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations. Transplantation 2005;80:157-163.
29. Avery RK. Management of late, recurrent, and resistant cytomegalovirus in transplant recipients. Transplant Rev 2007;21:65-76.
30. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002;34:1094-1097.
31. Chmiel C, Speich R, Hofer M, Michel D, Mertens T, Weder W, Boehler A. Ganciclovir/Valgnaciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation. Clin Infect Dis 2008;46:831-839.
32. Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. JAMA 1989;261:3607-3609.
33. Tolkoff-Rubin NE, Fishman JA, Rubin RH. The bidirectional relationship between cytomegalovirus and allograft injury. Transplant Proc 2001;33:1773-1775.
34. Boehler A, Estenne M. Obliterative bronchiolitis after lung transplantation. Curr Opin Pulm Med 2000;6:133-139.
35. Lehto JT, Halme M, Tukiainen P, Harjula A, Sipponen J, Lautenschlager I. Human herpesvirus-6 and -7 after lung and heart-lung transplantation. J Heart Lung Transplant 2007;26:41-47.
36. Manuel O, Kumar D, Singer LG, Cobos I, Humar A. Incidence and clinical characteristics of herpes zoster after lung transplantation. J Heart Lung Transplant 2008;27:11-16.
37. Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med 2005;56:29-44.
38. Reams BD, McAdams HP, Howell DN, Steele MP, Davis RD, Palmer SM. Posttransplant lymphoproliferative disorder: incidence, presentation and response to treatment in lung transplant recipients. Chest 2003;124:1242-1249.
39. Stevens SJ, Verschuuren EA, Pronk I, Harmsen MC, The TH, Meijer CJ, van Den Brule AJ, Middeldorp JM. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high risk patients. Blood 2001;97:1165-1171.
40. Bakker NA, Verschuuren EA, Erasmus ME, Hepkema BG, Veeger NJ, Kallenberg CG, van der Bij W. Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression. Transplantation 2007;83:433-438.
41. Gerna G, Vitulo P, Rovida F, Lilleri D, Pellegrini C, Oggionni T, Campanini G, Baldanti F, Revello MG. Impact of human metapneumovirus and human cytomegalovirus versus other respiratory viruses on the lower respiratory tract infections of lung transplant recipients. J Med Virol 2006;78:408-416.
42. Ohori NP, Michaels MG, Jaffe R, Williams P, Yousem SA. Adenovirus pneumonia in lung transplant recipients. Hum Pathol 1995;26:1073-1079.
43. Kaiser L, Aubert JD, Pache JC, Deffernez C, Rochat T, Garbino J, Wunderli W, Meylan P, Yerly S, Perrin L, et al. Chronic rhinoviral infection in lung transplant recipients. Am J Respir Crit Care Med 2006;174:1392-1399.
44. Billings JL, Hertz MI, Savik K, Wendt CH. Respiratory viruses and chronic rejection in lung transplant recipients. J Heart Lung Transplant 2002;21:559-566.
45. Khalifah AP, Hachem RR, Chakinala MM, Schechtman KB, Patterson GA, Schuster DP, Mohanakumar T, Trulock EP, Walter MJ. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med 2004;170:181-187.
46. Kumar D, Erdman D, Keshavjee S, Peret T, Tellier R, Hadjiliadis D, Johnson G, Ayers M, Siegal D, Humar A. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant 2005;5:2031-2036.
47. Milstone AP, Brumble LM, Barnes J, Estes W, Loyd JE, Pierson RN III, Dummer S. A single-season prospective study of respiratory viral infections in lung transplant recipients. Eur Respir J 2006;28:131-137.
48. Iwamoto M, Jernigan DB, Guasch A, Trepka MJ, Blackmore CG, Hellinger WC, Pham SM, Zaki S, Lanciotti RS, Lance-Parker SE, et al. West Nile Virus in Transplant Recipients Investigation Team. Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med 2003;348:2196-2203.
49. Kramer LD, Li J, Shi P-Y.WestNile virus. Lancet Neurol 2007;6:171-181.
50. Kumar D, Prasad GV, Zaltzman J, Levy GA, Humar A. Community acquired West Nile virus infection in solid-organ transplant recipients. Transplantation 2004;77:399-402.
51. Kumar D, Drebot MA, Wong SJ, Lim G, Arstob H, Buck P, Humar A. A seroprevalence study of West Nile virus infection in solid organ transplant recipients. Am J Transplant 2004;4:1883-1888.
52. Schwarz A, Mengel M, Haller H, Niedermeyer J. Polyoma virus nephropathy in native kidneys after lung transplantation. Am J Transplant 2005;5:2582-2585.
53. Doucette KE, Pang XL, Jackson K, Burton I, Carbonneau M, Cockfield S, Preiksaitis JK. Prospective monitoring of BK Polyomavirus infection early posttransplantation in nonrenal solid organ transplant recipients. Transplantation 2008;85:1733-1736.
54. Thomas LD, Vilchez RA, White ZS, Zanwar P, Milstone AP, Butel JS, Dummer S. A prospective longitudinal study of polyomavirus shedding in lung-transplant recipients. J Infect Dis 2007;195:442-449.
55. Kariyawasam HH, Gyi KM, Hodson ME, Cohen BJ. Anaemia in lung transplant patient caused by parvovirus B19. Thorax 2000;55:619-620.
56. Kumar D, Humar A. Emerging viral infections in transplant recipients. Curr Opin Infect Dis 2005;18:337-341.
57. Sole A, Salavert M. Fungal infections after lung transplantation. Transplant Rev 2008;22:89-104.
58. Singh N, Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implication for management. J Heart Lung Transplant 2003;22:258-266.
59. Kramer MR, Denning DW, Marshall SE, Ross DJ, Berry G, Lewiston NJ, Stevens DA, Theodore J. Ulcerative tracheobronchitis after lung transplantation: a new form of invasive aspergillosis. Am Rev Respir Dis 1991;144:552-556.
60. Mehrad B, Pacciocco G, Martinez FJ, Ojo TC, Iannettoni MD, Lynch JP. Spectrum of aspergillus infection in lung transplant recipients: case series and review of the literature. Chest 2001;119:169-175.
61. Segal BH, Walsh TJ. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med 2006;173:707-717.
62. Stewart S. Pulmonary infections in transplantation pathology. Arch Pathol Lab Med 2007;131:1219-1231.
63. Husain S, Kwak EJ, Obman A, Wagener MM, Kusne S, Stout JE, Mc Curry KR, Singh N. Prospective assessment of platelia Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. Am J Transplant 2004;4:796-802.
64. Husain S, Paterson DL, Studer SM, Crespo M, Pilewski J, Durkin M, Wheat JL, Johnson B, Mc Laughlin L, Bentensen C, et al. Aspergillus galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients. Transplantation 2007;83:1330-1336.
65. Palmer SM, Alexander BD, Sanders LL, Edwards LJ, Reller LB, Davis RD, Tapson VF. Significance of blood stream infection after lung transplantation: analysis in 176 consecutive patients. Transplantation 2000;69:2360-2366.
66. Palmer SM, Perfect JR, Howell DN, Lawrence CM, Miralles AP, Davis RD, Tapson VF. Candidal anastomotic infection after lung transplantation: successful treatment with a combination of systemic and inhaled antifungal agents. J Heart Lung Transplant 1998;17:1029-1033.
67. Orens JB, Annette Boehler A, de Perrot M, Estenne M, Glanville AR, Shaf Keshavjee S, Kotloff R, Morton J, Studer SM, Van Raemdonck D, et al. Review of lung transplant donor acceptability criteria. J Heart Lung Transplant 2003;22:1183-1200.
68. Almyroudis NG, Sutton DA, Linden P, Rinaldi MG, Fung J, Kusne S. Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transplant 2006;6:2365-2374.
69. Tamm M, Malouf M, Glanville A. Pulmonary Scedosporium infection following lung transplantation. Transpl Infect Dis 2001;3:189-194.
70. Musk M, Chambers D, Chin W, Murray R, Gabbay E. Successful treatment of disseminated scedosporium infection in 2 lung transplant recipients: review of the literature and recommodations for management. J Heart Lung Transplant 2006;25:1268-1272.
71. Arney KL, Tiernan R, Judson MA. Primary pulmonary involvement of Fusarium solani in a lung transplant recipient. Chest 1997;112:1128-1130.
72. Sampathkumar P, Paya CV. Fusarium infection after solid organ transplantation. Clin Infect Dis 2001;32:1237-1240.
73. Herbrecht R, Kessler R, Kravanja C, Meyer M-H, Waller J, Letscher-Bru V. Successful treatment of Fusarium proliferatum pneumonia with posaconazole in a lung transplant recipient. J Heart Lung Transplant 2004;23:1451-1454.
74. Green M, Avery RK. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 2004;4(Suppl 10):160-163.
75. Avery RK, Michaels M. Update on immunizations in solid organ transplant recipients: what clinicians need to know. Am J Transplant 2008;8:9-14.
76. Ballout A, Goffin E, Yombi JC, Vandercam B. Vaccinations for adult solid organ transplant recipient: current recommendations. Transplant Proc 2005;37:2826-2827.
77. Benden C, Danziger-Isakov LA, Astor T, Aurora P, Bluemchen K, Boyer D, Conrad C, Eichler I, Elidemir O, Goldfarb S, et al. Variability in immunization guidelines in children before and after lung transplantation. Pediatr Transplant 2007;11:882-887.
78. Hodson EM, Craig JC, Strippoli GF, Webster AC. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2008;(2):CD003774.
79. Zamora MR, Nicolls MR, Hodges TN, Marquesen J, Astor T, Grazia T, Weill D. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant 2004;4:1635-1642.
80. Valentine VG, Weill D, Gupta MR, Raper B, Laplace SG, Lombard GA, Bonvillain RW, Taylor DE, Dhillon GS. Ganciclovir for cytomegalovirus: a call for indefinite prophylaxis in lung transplantation. J Heart Lung Transplant 2008;27:875-881.
81. Husain S, Zaldonis D, Kusne S, Kwak EJ, Paterson DL, McCurry KR. Variation in antifungal prophylaxis strategies in lung transplantation. Transpl Infect Dis 2006;8:213-218.
82. Husain S, Paterson DL, Studer S, Pilewski J, Crespo M, Zaldonis D, Shutt K, Pakstis DL, Zeevi A, Johnson B, et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006;6:3008-3016.